CorMedix financials
$7.93+0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | $0.00 | $65.4K | $190.9K | $239.2K | $283.3K | $429.8K | $329.3K | $224.1K |
| Gross profit | $275.7M | $40.3M | $0.00 | $61.7K | $42.0K | $34.4K | -$90.0K | $33.0K | $214.4K | -$142.6K |
| Gross margin | 88.5% | 92.7% | — | 94.3% | 22.0% | 14.4% | −31.8% | 7.7% | 65.1% | −63.6% |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M | -$29.4M | -$27.2M | -$21.0M | -$26.9M | -$32.9M | -$24.8M |
| Net income | $163.1M | -$17.9M | -$46.3M | -$29.7M | -$28.2M | -$22.0M | -$43.5M | -$26.8M | -$33.0M | -$24.6M |
| Net margin | 52.3% | −41.2% | — | −45409.9% | −14774.7% | −9207.7% | −15369.2% | −6242.4% | −10023.4% | −10996.5% |
| Diluted EPS | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 | $-0.77 | $-1.80 | $-1.51 | $-0.60 | $-3.25 |
| EBITDA | $164.7M | -$22.0M | -$48.9M | -$30.4M | -$29.3M | -$27.1M | -$20.9M | -$26.8M | -$32.9M | -$24.7M |
| Operating cash flow | $175.0M | -$50.6M | -$38.4M | -$24.4M | -$21.2M | -$22.0M | -$15.1M | -$23.7M | -$28.6M | -$22.3M |
| Free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M | -$22.6M | -$22.1M | -$15.1M | -$23.7M | -$28.7M | -$22.3M |
| Diluted shares | 80.3M | 58.9M | 50.9M | 40.3M | 37.7M | 28.6M | 24.2M | 17.8M | 55.1M | 7.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $144.8M | $40.7M | $43.6M | $43.1M | $53.3M | $41.9M |
| Short-term investments | $3.7M | $11.0M | $32.4M | $15.6M | $12.1M | $4.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $826.1M | $118.8M | $82.1M | $62.0M | $68.9M | $49.3M |
| Total liabilities | $420.8M | $34.2M | $11.9M | $7.0M | $6.1M | $5.1M |
| Shareholders' equity | $405.3M | $84.7M | $70.1M | $55.1M | $62.8M | $44.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology